Tapering Keppra (Levetiracetam) Protocol

Introduction to Tapering

The American Academy of Neurology recommends tapering Keppra by reducing the dose by 500 mg every 2 weeks until reaching 500 mg daily, then reducing to 250 mg daily for 2 weeks, followed by 250 mg every other day for 2 weeks before discontinuation, to minimize withdrawal symptoms and prevent seizure recurrence [2].

For patients on doses >1000 mg/day, the recommended tapering schedule is to reduce by 500 mg every 2 weeks until reaching 1000 mg/day, then reduce by 250-500 mg every 2 weeks until reaching 500 mg/day, and finally reduce to 250 mg daily for 2 weeks before switching to 250 mg every other day for 2 weeks [2].
For patients with seizure disorders, a slower taper of 250 mg reduction every 4 weeks may be considered, with close monitoring for breakthrough seizures, and the taper may need to be paused if seizure activity increases [2].
For patients on high doses (>3000 mg/day), initial reductions can be larger (500-1000 mg every 2 weeks), but should slow to 250 mg reductions when reaching 1000 mg/day [2].

During pregnancy, tapering Keppra requires special expertise due to potential risks to both mother and fetus, according to the Centers for Disease Control and Prevention [1].
Elderly patients may benefit from an even slower tapering schedule (250 mg reduction every 4 weeks) [2].
Patients with renal impairment may require dose adjustments based on creatinine clearance [2].

Regular follow-up is essential, with weekly monitoring during the first phase of tapering, and more frequent monitoring for patients with a history of severe seizures [2].
If withdrawal symptoms emerge, or if seizures recur or increase in frequency, the taper should be paused for 2-4 weeks before resuming at a slower rate [2].
If seizures recur during or after tapering, the patient should return to the last effective dose, and consider maintenance at a lower dose than originally prescribed, or re-evaluate the need for continued therapy or alternative medications [2].